Trial Profile
A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cyclophosphamide; Doxorubicin; Filgrastim; Paclitaxel; Pegfilgrastim
- Indications Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpassion031
- Sponsors Chugai Pharmaceutical; Roche
- 24 Oct 2023 Results assessing exploratory biomarker analysis presented at the 48th European Society for Medical Oncology Congress.
- 08 Dec 2022 This trial has been Completed in Germany, According to European Clinical Trials Database record.
- 15 Nov 2022 Status changed from active, no longer recruiting to completed.